Subtype
Large Intestinal Neoplasm
CI-CAN-00001062Explore in graph →
Non-malignant1,847 active trials21 approved drugs383 evidence items
- NCIt
- C215201
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001062Explore in graph →
Clinical trials
8,849 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00819780 | PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors | completed | Phase 2 | 285 | AmgenINDUSTRY | 6 | Dec 6, 2022 | clinicaltrials |
| NCT01874860 | Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients | completed | Phase 2 | 24 | University of LouisvilleOTHER | 1 | Dec 1, 2022 | clinicaltrials |
| NCT05622357 | Prospective Study of Short Course Radiation Therapy Followed by Neoadjuvant Chemotherapy and Surgery in Locally Advanced Rectal Cancer | completed | Phase 2 | 51 | National Cancer Institute, EgyptOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT01326000 | A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 169 | Hoffmann-La RocheINDUSTRY | 9 | Nov 17, 2022 | clinicaltrials |
| NCT00089635 | Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 203 | AmgenINDUSTRY | 0 | Nov 7, 2022 | clinicaltrials |
| NCT00467142 | Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery(OMEGA) | completed | Phase 2 | 62 | Institut BergoniéOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT02713373 | Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 45 | Roswell Park Cancer InstituteOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03174405 | Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.(AVETUX) | completed | Phase 2 | 43 | AIO-Studien-gGmbHOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT03965845 | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 53 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 19, 2022 | clinicaltrials |
| NCT03227926 | Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance(CHRONOS) | completed | Phase 2 | 32 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Aug 25, 2022 | clinicaltrials |
| NCT01064375 | Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer(El-porCEA) | completed | Phase 1 / Phase 2 | 16 | Maria LiljeforsOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT02569645 | Rosuvastatin in the Treatment of Rectal Cancer | completed | Phase 2 | 45 | AHS Cancer Control AlbertaOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT03542877 | Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 2 | 44 | Academic Thoracic Oncology Medical Investigators ConsortiumINDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT04080843 | Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients(ALTER-C-002) | completed | Phase 2 | 30 | Zhejiang UniversityOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT03122509 | A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer | completed | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT03086538 | Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy | completed | Phase 2 | 29 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05414461 | Efficacy of Combination Immunotherapy in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 97 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT03332498 | Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers | completed | Phase 1 / Phase 2 | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT03101475 | Synergism of Immunomodulation and Tumor Ablation(ILOC) | completed | Phase 2 | 22 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | May 31, 2022 | clinicaltrials |
| NCT03391232 | PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO)(OBERTO) | completed | Phase 1 / Phase 2 | 11 | Treos Bio ZrtINDUSTRY | 2 | May 26, 2022 | clinicaltrials |
| NCT02399943 | A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer | completed | Phase 2 | 14 | University Health Network, TorontoOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT02402842 | Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma(Epitopes-HPV02) | completed | Phase 2 | 70 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT04561336 | Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer | completed | Phase 2 | 77 | University of Campania Luigi VanvitelliOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT03666442 | Early Evaluation of Chemosensitivity for Low/Intermediated-risk Mid-low Stage II/III Rectal Cancer | completed | Phase 2 | 61 | West China HospitalOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT01516216 | Study of Vitamin D in Untreated Metastatic Colorectal Cancer | completed | Phase 2 | 139 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT03102047 | Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer | completed | Phase 2 | 45 | NSABP Foundation IncNETWORK | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03799731 | Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers | completed | Phase 2 | 65 | GamaMabs PharmaINDUSTRY | 2 | Apr 14, 2022 | clinicaltrials |
| NCT04425239 | Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer(IMPROVE) | completed | Phase 2 | 151 | National Cancer Institute, NaplesOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT05316818 | Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma | completed | Phase 2 | 64 | Kasr El Aini HospitalOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT03832621 | NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer(MAYA) | completed | Phase 2 | 135 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT02439385 | Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis | completed | Phase 2 | 44 | Gachon University Gil Medical CenterOTHER | 0 | Mar 31, 2022 | clinicaltrials |
| NCT02404935 | Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)(TIME) | completed | Phase 2 | 139 | UNICANCEROTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT03000374 | Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery(PIER) | completed | Phase 2 | 34 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT04247984 | A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer | completed | Phase 2 | 264 | Chinese Academy of Medical SciencesOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05274945 | Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer | completed | Phase 2 | 58 | Alexandria UniversityOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT03254394 | Lidocaine for Oxaliplatin-induced Neuropathy | completed | Phase 1 / Phase 2 | 26 | Washington University School of MedicineOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT03359681 | Metformin Treatment for Colon Cancer(MECORA) | completed | Phase 2 | 48 | Zealand University HospitalOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03454620 | A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy | completed | Phase 1 / Phase 2 | 53 | Green Cross CorporationINDUSTRY | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03403634 | Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver | completed | Phase 2 | 19 | Roswell Park Cancer InstituteOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT02375672 | Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer | completed | Phase 2 | 30 | Hoosier Cancer Research NetworkOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02292758 | Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 36 | Academic and Community Cancer Research UnitedOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT00193219 | Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 36 | SCRI Development Innovations, LLCOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT00308516 | 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer | completed | Phase 2 | 66 | SCRI Development Innovations, LLCOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT03384940 | DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) | completed | Phase 2 | 86 | Daiichi Sankyo Co., Ltd.INDUSTRY | 5 | Oct 18, 2021 | clinicaltrials |
| NCT00803647 | A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver | completed | Phase 2 | 20 | NSABP Foundation IncNETWORK | 1 | Oct 6, 2021 | clinicaltrials |
| NCT01535040 | Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking | completed | Phase 2 | 130 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT03803241 | Cd133+ Cell Infusion in Patients With Colorectal Liver Metastases.(cellcol) | completed | Phase 2 | 4 | Hospital San Carlos, MadridOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT00640081 | Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer | completed | Phase 2 | 169 | Cheryl PughOTHER_GOV | 2 | Sep 22, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Dec 6, 2022source: clinicaltrials